<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453672</url>
  </required_header>
  <id_info>
    <org_study_id>SB8-G11-NHV</org_study_id>
    <secondary_id>2015-001026-41</secondary_id>
    <nct_id>NCT02453672</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects</brief_title>
  <official_title>A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of
      Bevacizumab
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the
      Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of
      Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to infinity (AUCinf)</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum serum concentration (Cmax)</measure>
    <time_frame>Day 85</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>SB8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SB8, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EU Sourced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EU Sourced Avastin®, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US Sourced Avastin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>US Sourced Avastin®, single dose of 3 mg/kg, IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SB8</intervention_name>
    <description>SB8, proposed bevacizumab biosimilar</description>
    <arm_group_label>SB8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>EU sourced Avastin®</intervention_name>
    <description>EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
    <arm_group_label>EU Sourced Avastin®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>US Sourced Avastin®</intervention_name>
    <description>US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)</description>
    <arm_group_label>US Sourced Avastin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects

          -  Have body weight between 65.0-90.0 kg (inclusive) and body mass index between
             20.0-29.9 kg/m2 (inclusive)

        Exclusion Criteria:

          -  Have a history of hypersensitivity or allergic reactions to bevacizumab or to any of
             the excipients

          -  Have a history of and/or current clinically significant gastrointestinal, renal,
             hepatic, cardiovascular, haematological, pulmonary, neurologic, metabolic,
             psychiatric, or allergic disease excluding mild asymptomatic seasonal allergies

          -  Have a history of arterial thromboembolic events including cerebrovascular accidents,
             transient ischaemic attacks, and myocardial infarction

          -  Have a history of and/or current cardiac disease

          -  Have previously been exposed to vascular endothelial growth factor (VEGF) antibody,
             any other antibody, or protein targeting the VEGF receptor

          -  Have a history of cancer including lymphoma, leukaemia, and skin cancer.

          -  Have received live vaccine(s) within 30 days prior to Screening visit or who will
             require a vaccine(s) between Screening and the end of study visit

          -  Have taken medication with a half-life of &gt; 24 hours within 30 days or 10 half-lives
             of the medication prior to the IP administration
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Investigational Site</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

